Wall Street analysts predict that MacroGenics Inc (NASDAQ:MGNX) will report $7.46 million in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for MacroGenics’ earnings, with the highest sales estimate coming in at $16.55 million and the lowest estimate coming in at $1.85 million. MacroGenics reported sales of $2.06 million in the same quarter last year, which indicates a positive year-over-year growth rate of 262.1%. The business is expected to report its next quarterly earnings report on Wednesday, May 2nd.
According to Zacks, analysts expect that MacroGenics will report full-year sales of $7.46 million for the current fiscal year, with estimates ranging from $12.00 million to $84.15 million. For the next year, analysts forecast that the company will report sales of $46.64 million per share, with estimates ranging from $4.00 million to $105.90 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for MacroGenics.
A number of analysts recently issued reports on the company. Zacks Investment Research cut MacroGenics from a “hold” rating to a “sell” rating in a research report on Friday, February 23rd. ValuEngine upgraded MacroGenics from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. BidaskClub lowered MacroGenics from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 14th. Cowen restated a “buy” rating on shares of MacroGenics in a research note on Wednesday, January 24th. Finally, Morgan Stanley restated an “equal weight” rating and set a $26.00 price target (up from $18.00) on shares of MacroGenics in a research note on Wednesday, March 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company’s stock. MacroGenics currently has a consensus rating of “Buy” and an average target price of $29.78.
Shares of MacroGenics stock traded down $0.24 during trading on Friday, hitting $29.45. The stock had a trading volume of 150,539 shares, compared to its average volume of 264,899. The firm has a market capitalization of $1,096.12, a PE ratio of -42.10 and a beta of 2.52. MacroGenics has a 1-year low of $14.36 and a 1-year high of $32.74.
In other MacroGenics news, VP Lynn Cilinski sold 23,967 shares of MacroGenics stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $25.01, for a total transaction of $599,414.67. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Eric Blasius Risser sold 3,000 shares of the company’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $22.50, for a total value of $67,500.00. Following the transaction, the senior vice president now directly owns 12,100 shares in the company, valued at approximately $272,250. The disclosure for this sale can be found here. Insiders have sold 42,967 shares of company stock worth $1,098,005 over the last ninety days. Company insiders own 8.30% of the company’s stock.
Several institutional investors have recently modified their holdings of MGNX. Parametric Portfolio Associates LLC bought a new position in shares of MacroGenics during the second quarter worth approximately $203,000. Dimensional Fund Advisors LP lifted its holdings in shares of MacroGenics by 314.8% during the second quarter. Dimensional Fund Advisors LP now owns 180,739 shares of the biopharmaceutical company’s stock worth $3,165,000 after purchasing an additional 137,167 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in MacroGenics by 2.9% in the second quarter. The Manufacturers Life Insurance Company now owns 26,485 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 743 shares during the period. Los Angeles Capital Management & Equity Research Inc. lifted its holdings in MacroGenics by 19.3% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 31,210 shares of the biopharmaceutical company’s stock valued at $577,000 after buying an additional 5,050 shares during the period. Finally, DekaBank Deutsche Girozentrale lifted its holdings in MacroGenics by 9.6% in the third quarter. DekaBank Deutsche Girozentrale now owns 228,500 shares of the biopharmaceutical company’s stock valued at $3,745,000 after buying an additional 20,000 shares during the period. Institutional investors own 91.13% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/03/19/zacks-analysts-expect-macrogenics-inc-mgnx-will-announce-quarterly-sales-of-7-46-million.html.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Get a free copy of the Zacks research report on MacroGenics (MGNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.